BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering shares at an expected price between $17.00 and $19.00 per share with an ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...

"IG index spreads narrowed 0-1bp during yesterday’s session, and the ICE Corporate index opens this morning at a spread to Treasuries of 92bp. That’s the narrowest spread for the IG index since July ...

The Richmond, California-based company is now seeking to raise as much as $199.5 million by offering 10.5 million shares at $17 to $19 each. BioAge Labs will list on the Nasdaq Global Market under the ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

The Dallas-based company focuses on so-called outparcels, properties that point directly onto high-traffic roads that are visible to consumers, and Illinois is its largest market.

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in a ...

The IPO market has become red hot — at least among venture capital–backed biopharma and other life sciences companies. In the ...

The U.S. IPO market looks stable this week, with a few new companies aiming to raise capital, as the Federal Reserve reduced ...